Table 3.
Cell-based therapies for lacrimal gland regeneration.
| Type of cells/conditioned medium | Mode of experiment and impact | References |
|---|---|---|
| Induced Pluripotent stem cells (iPS) -derived conditioned medium | Injection in mouse Tail-vein 1h before irradiation; Partially-improved tear secretion | (91) |
| Injection of xenogeneic human MSCs (hMSCs) into the periorbital space of an inflammation concanavalin induced dry eye mouse model | 103-105 Hmsc per mouse eye injected after causing inflammation Restored tear secretion (1 week post concanavalin injection)—reduced T cell inflammation | (82) |
| Injection of allogeneic MSCs into the area surrounding the main lacrimal gland of dogs with naturally occurring DES | Used 8 × 106 hMSC/dog eye Schirmer test score restored to with normal range. Ocular discharge reduced -hyperemia reduced –corneal changes reduced | (80) |
| Topical administration of Autologous MSC to the corneas of rats following benzalkonium Chloride to induce DES |
7 × 105 MSC per rate Schirmer Test Score Increased -TBUT increased -corneal defects reduced | (78) |
| Intravenous (IV) injection of allogeneic MSC to patients with DES secondary to GVHD | 1 × 106 MSC/kg -Schirmer test score increased -TBUT increased -corneal defects reduced | (81) |
| Salivary gland, Tail-vein injection of allogeneic BM-MSC into a mice model of SS |